Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (29918)	1/7/2000 9:26:00 AM
From: Torben Noerup Nielsen	Read Replies (2) \| Respond to of 32384

Celery, I presume it's the labeling that would take the most effort. As far as I know, there aren't government price controls in place in Europe for medications; merely insurance issues. I recall hearing that we generally pay more for drugs in the US than people do overseas and thus the US market is worth a fair bit more than the number of patients would seem to indicate. Thanks, Torben

To: celeryroot.com who wrote (29918)	1/7/2000 2:03:00 PM
From: NeuroInvestment	Read Replies (3) \| Respond to of 32384

I was asked to comment on this: EU Registration is not yet one-step, or at least, many companies are not pursuing EU-wide applications. Instead, they are picking the country where they believe they have the fastest track. Once approved there, that approval is submitted to the rest of the EU, and those approvals are more pro forma. However, pricing approvals at present are still country by country, and are not pro forma. They can be quite slow and laborious. NeuroInvestment (www.neuroinvestment.com)